T-cell/histiocyte rich large B cell lymphoma
MONDO:0017597T-cell/histiocyte rich large B cell lymphoma (THRLBCL) is a rare variant of diffuse large B-cell lymphoma (DLBCL), mainly affecting middle-aged men and often not being discovered until an advanced disease stage, with involvement of the spleen, liver and bone marrow occurring at a greater frequency than in DLBCL. It is often difficult to diagnose due to its similarity with other lymphoid diseases such as classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma and has an aggressive clinical course.
Also known as: T-cell rich/histiocyte-rich large B-cell lymphoma, T-cell/histiocyte rich lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, THRLBCL
2026 clinical trials for this condition and its sub-types, 31 tagged with T-cell/histiocyte rich large B cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a Faster-Dosed antibody drug paired with lenalidomide help lymphoma that came back after CAR T-Cell therapy?
Disease control Not yet recruitingResearchers are testing a combination of two drugs, epcoritamab and lenalidomide, in adults whose large B-cell lymphoma has come back after CAR T-cell therapy. The trial enrolls about 55 people in France. Participants receive epcoritamab as a shot under the skin using a faster do…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for lymphoma: immune booster plus chemotherapy trial launches
Disease control Not yet recruitingThis Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…
Phase 2 • Sponsor: Carrie Ho, MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: three-drug combo enters early trials
Disease control Not yet recruitingThis early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…
Phase 1/2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC